

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**AUDITED FINANCIAL RESULTS
FOR THE YEAR ENDED 31ST DECEMBER, 2008**

(Rs. lakhs)

Unaudited			Audited	
3 months ended 31.12.2008	3 months ended 31.12.2007		Year ended 31.12.2008	Year ended 31.12.2007
38434	36785	Sales	175156	171284
1589	2858	Less: Excise Duty on Sales	9115	13570
36845	33927	Net Sales	166041	157714
642	748	Other Operating Income	2027	1903
37487	34675	Income from Operations	168068	159617
		Expenditure		
(2571)	(707)	(Increase) / decrease in stock-in-trade and work in progress	(233)	3273
11028	6533	Consumption of raw and packing materials	35187	32152
6364	7798	Purchase of traded goods	29807	29365
-	-	Transfer of stock pursuant to sale of business	-	(1944)
14821	13624	Total materials consumed	64761	62846
(109)	4	Excise duty on samples and (increase) / decrease in stock-in-trade	(488)	684
4252	3326	Employees cost	17275	15570
473	502	Depreciation	1634	1616
8606	8201	Other expenditure	30860	30008
(223)	(80)	Recovery of expenses (net)	(796)	(673)
(979)	(946)	Expenses relating to service income	(3340)	(4027)
12020	11007	Total operating expenses	45145	43178
26841	24631	Total	109906	106024
10646	10044	Profit from Operations before Other Income, Interest and Exceptional Items	58162	53593
66	1037	Other Income (net) [includes treasury income Rs. 48 lakhs (previous quarter Rs. 1024 lakhs)]	2826	2558
2976	1082	Interest Income (net)	7002	4523
13688	12163	Profit before Tax and Exceptional Items	67990	60674
		Tax Expense		
4807	3735	Current tax (including fringe benefits tax)	23387	19930
(35)	434	Deferred tax	(233)	1065
4772	4169	Total	23154	20995
8916	7994	Net Profit after Tax before Exceptional Items	44836	39679
11931	96	Exceptional Items (net of tax)	12821	14087
20847	8090	Net Profit	57657	53766
8470	8470	Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470
		Reserves excluding Revaluation Reserves	145639	127621
		Earnings Per Share (EPS)		
10.5	9.4	Basic and diluted EPS before exceptional items (Rs.)	52.9	46.8
24.6	9.6	Basic and diluted EPS after exceptional items (Rs.)	68.1	63.5
		Public Shareholding		
41785529	41785529	Number of shares	41785529	41785529
49.3%	49.3%	Percentage of shareholding	49.3%	49.3%

1. The growth in Net Sales (net of excise duty), excluding the Fine Chemicals business which was divested last year, was 10.1% and in Profit before Tax and Exceptional Items was 14.6% for the year ended 31st December, 2008 on a comparable basis. The growth in Gross Sales was impacted due to the sale of the Fine Chemicals business as on 30th September, 2007 and on account of lower selling prices as a result of the benefit of excise duty reduction being passed on to the consumer.

The figures for the year ended 31st December, 2008 are not comparable with those of the previous year in view of the sale of the Fine Chemicals business on 30th September 2007.

2. Exceptional items (net of tax) for the year ended 31st December, 2008 include profit on sale / redemption of investments Rs. 14603 lakhs and actuarial provision on employee benefits Rs. 1551 lakhs.

3. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

4. There were no investor complaints pending as at the beginning of the quarter. The Company has received 6 complaints from the investors during the quarter and all of them have since been resolved, leaving no investor complaints unresolved at the end of the quarter.

5. The Board of Directors recommends a Dividend of Rs. 22 per equity share (Previous year Rs. 18 per equity share) and a special additional Dividend of Rs. 18 per equity share (Previous year Rs. 18 per equity share).

6. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 18th February, 2009.

7. The figures for 2007 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

Dr. Hasit B. Joshipura
Managing Director

18th February, 2009